Sigma Planning Corp Lowers Holdings in Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN)

Sigma Planning Corp cut its position in Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) by 4.5% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 18,968 shares of the company’s stock after selling 900 shares during the quarter. Sigma Planning Corp’s holdings in Biohaven Pharmaceutical were worth $791,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of BHVN. Nisa Investment Advisors LLC increased its holdings in shares of Biohaven Pharmaceutical by 511.1% in the 3rd quarter. Nisa Investment Advisors LLC now owns 1,100 shares of the company’s stock worth $46,000 after buying an additional 920 shares during the last quarter. Tower Research Capital LLC TRC bought a new position in shares of Biohaven Pharmaceutical in the 2nd quarter worth $65,000. Aperio Group LLC bought a new position in shares of Biohaven Pharmaceutical in the 2nd quarter worth $71,000. Glen Harbor Capital Management LLC increased its holdings in shares of Biohaven Pharmaceutical by 165.9% in the 2nd quarter. Glen Harbor Capital Management LLC now owns 1,744 shares of the company’s stock worth $76,000 after buying an additional 1,088 shares during the last quarter. Finally, Canton Hathaway LLC bought a new position in shares of Biohaven Pharmaceutical in the 3rd quarter worth $83,000. Institutional investors and hedge funds own 90.74% of the company’s stock.

In other Biohaven Pharmaceutical news, Director Eric Aguiar sold 10,000 shares of the firm’s stock in a transaction on Wednesday, September 11th. The shares were sold at an average price of $45.00, for a total value of $450,000.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Elyse Stock sold 800 shares of the firm’s stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $45.01, for a total transaction of $36,008.00. Following the completion of the sale, the insider now directly owns 800 shares in the company, valued at approximately $36,008. The disclosure for this sale can be found here. In the last three months, insiders sold 28,500 shares of company stock worth $1,283,747. Insiders own 23.90% of the company’s stock.

BHVN stock opened at $46.01 on Friday. Biohaven Pharmaceutical Holding Co Ltd has a 52 week low of $29.17 and a 52 week high of $67.86. The firm’s fifty day moving average is $44.64 and its 200 day moving average is $48.15. The firm has a market cap of $2.45 billion, a P/E ratio of -7.48 and a beta of 0.34.

Biohaven Pharmaceutical (NYSE:BHVN) last announced its quarterly earnings results on Friday, November 1st. The company reported ($2.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.57) by ($0.47). As a group, equities analysts predict that Biohaven Pharmaceutical Holding Co Ltd will post -7.68 earnings per share for the current fiscal year.

BHVN has been the topic of a number of research analyst reports. Oppenheimer set a $67.00 price target on shares of Biohaven Pharmaceutical and gave the stock a “buy” rating in a report on Wednesday, October 9th. ValuEngine raised shares of Biohaven Pharmaceutical from a “sell” rating to a “hold” rating in a report on Friday, November 1st. Morgan Stanley set a $50.00 target price on shares of Biohaven Pharmaceutical and gave the company a “hold” rating in a report on Friday, August 9th. Cantor Fitzgerald increased their target price on shares of Biohaven Pharmaceutical from $87.00 to $92.00 and gave the company an “overweight” rating in a report on Monday, October 28th. Finally, Goldman Sachs Group set a $89.00 target price on shares of Biohaven Pharmaceutical and gave the company a “buy” rating in a report on Wednesday, September 4th. Four investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $69.82.

About Biohaven Pharmaceutical

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials and is in long-term safety ongoing process for acute treatment and prevention of migraine; BHV-3500 that has completed phase I clinical trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias.

Featured Article: After-Hours Trading

Want to see what other hedge funds are holding BHVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN).

Institutional Ownership by Quarter for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.